Because of the heterogeneity of HER2+ breast cancer and the complex mechanism of HER2 and AR, better understanding of the prognostic value of AR in all HER2+ and HER2+ hormone receptor-negative (HR−) nonmetastatic breast invasive ductal carcinoma (IDC) patients is urgent. Here, ERBB2 is linked to breast carcinoma.